<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374398</url>
  </required_header>
  <id_info>
    <org_study_id>10-1-M-194</org_study_id>
    <nct_id>NCT02374398</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)</brief_title>
  <official_title>A Randomized, Controlled Clinical Trial Comparing the Use of Intravenous Tranexamic Acid With Aquamantys Bipolar Sealer for Blood Loss Reduction in Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Maine Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine if the use of iv TXA or Aquamantys system improve the
      postoperative hemoglobin and hematocrit after primary TKA and what is the effect of the
      simultaneous use of iv TXA and Aquamantys on the postoperative hemoglobin and hematocrit. The
      assumption is that the combination of iv TXA and Aquamantys system will enable an improvement
      in the postoperative hemoglobin and hematocrit equal or larger than the improvement generated
      by the use of Aquamantys system alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is randomized, placebo controlled. The study population includes patients older
      than 18 years of age undergoing elective total primary knee replacement under spinal
      anesthesia. All patients enrolled in the study will undergo TKA performed by the same
      orthopedic surgeon. Since controversies exist regarding the effect of different types of
      anesthesia (general anesthesia versus spinal or epidural anesthesia) on intraoperative blood
      loss, in order to eliminate an important confounding variable we decided to exclusively
      enroll for our study patients that qualify for and agree with spinal anesthesia to be used as
      the main anesthetic technique for their TKA.

      All clinical trial procedures will be performed by personnel blinded to study treatment
      assignment. Unblinding is only allowed for safety concerns in an emergency situation.The only
      other exception is represented by the surgeon, who can't be blinded in regards to using
      Aquamantys system and the bipolar sealer. Once a subject becomes eligible for the trial, the
      investigator or the designee will access the randomization system.

      Enrolled subjects will be assigned to one of the 4 groups by block randomization of
      alternating 4 and 8 and 12 patients per block. The Pharmacy Department will provide the iv
      placebo or the iv TXA according to the randomization process.

      This clinical trial will be conducted in accordance to this protocol, Good Clinical Practice
      and applicable regulatory requirements
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Hemoglobin (Hb) From the Day of Surgery</measure>
    <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
    <description>Control group- iv placebo normal saline plus regular electrocautery.
iv TXA plus regular electrocautery.
iv placebo plus Aquamantys system and regular electrocautery.
iv TXA and Aquamantys system and regular electrocautery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Hematocrit (Ht) From the Day of Surgery</measure>
    <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
    <description>Control group- iv placebo normal saline plus regular electrocautery.
iv TXA plus regular electrocautery.
iv placebo plus Aquamantys system and regular electrocautery.
iv TXA and Aquamantys system and regular electrocautery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Blood Loss</measure>
    <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
    <description>The estimated blood loss was determined with the Gross formula [23]. According to a review article published in 2013, Gross's formula though developed in 1983 is still widely used as reported. The formula which is relatively easy to use is described below:
Patient blood volume (PBV) = K (1) x height (m) 3 + K (2) x weight (kg) + K (3) Where K (1) = 0.3669 (male), 0.3561(female); K (2) = 0.03219 (male), 0.03308 (female); And K (3) = 0.6041(male), 0.1833 (female) Estimated blood loss = PBV [Hematocritinitial - Hematocritfinal ] / Hematocritmean Where mean hematocrit is the sum of initial and final hematocrit divided by two.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Analysis</measure>
    <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
    <description>Charges per case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
    <description>Complications: deep venous thrombosis(DVT) or arterial thrombosis, pulmonary embolism(PE), myocardial infarction (MI), cerebrovascular accident (CVA)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aquamantys System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TXA plus Aquamantys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>see arm/group descriptions</description>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_label>TXA plus Aquamantys</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquamantys System</intervention_name>
    <description>see arm/group descriptions</description>
    <arm_group_label>Aquamantys System</arm_group_label>
    <arm_group_label>TXA plus Aquamantys</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard Electro-cautery and Saline</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients over age of 18 undergoing elective total primary knee arthroplasty
             under spinal anesthesia.

        Exclusion Criteria:

          -  Previous adverse reaction to tranexamic acid

          -  Congenital or acquired coagulation disorders

          -  Preoperative platelet count of less than 100,000/microliter or INR&gt; 1.4

          -  History of deep venous thrombosis, pulmonary embolism or cerebrovascular accident

          -  Patients with acquired defective color vision

          -  Renal insufficiency (Glomerular filtration rate &lt;20 ml/min)

          -  Severe liver disease

          -  Coronary stents

          -  Pregnant patients

          -  Main anesthetic other than spinal anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Sorondo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eastern Maine Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S2352344116000029</url>
    <description>Published article</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <results_first_submitted>August 10, 2016</results_first_submitted>
  <results_first_submitted_qc>November 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2017</results_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Maine Medical Center</investigator_affiliation>
    <investigator_full_name>Alexandru Seviciu, MD</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Blood Loss</keyword>
  <keyword>Aquamantys System</keyword>
  <keyword>TKA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid</title>
          <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
        </group>
        <group group_id="P2">
          <title>Aquamantys System</title>
          <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
        </group>
        <group group_id="P3">
          <title>TXA Plus Aquamantys</title>
          <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
          <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid</title>
          <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
        </group>
        <group group_id="B2">
          <title>Aquamantys System</title>
          <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
        </group>
        <group group_id="B3">
          <title>TXA Plus Aquamantys</title>
          <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
          <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="8.6"/>
                    <measurement group_id="B2" value="64.8" spread="8.0"/>
                    <measurement group_id="B3" value="61.1" spread="10.5"/>
                    <measurement group_id="B4" value="62.9" spread="8.4"/>
                    <measurement group_id="B5" value="63.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Hemoglobin (Hb) From the Day of Surgery</title>
        <description>Control group- iv placebo normal saline plus regular electrocautery.
iv TXA plus regular electrocautery.
iv placebo plus Aquamantys system and regular electrocautery.
iv TXA and Aquamantys system and regular electrocautery</description>
        <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
          </group>
          <group group_id="O2">
            <title>Aquamantys System</title>
            <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O3">
            <title>TXA Plus Aquamantys</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Hemoglobin (Hb) From the Day of Surgery</title>
          <description>Control group- iv placebo normal saline plus regular electrocautery.
iv TXA plus regular electrocautery.
iv placebo plus Aquamantys system and regular electrocautery.
iv TXA and Aquamantys system and regular electrocautery</description>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.9"/>
                    <measurement group_id="O2" value="3.2" spread="1.1"/>
                    <measurement group_id="O3" value="2.6" spread="1.0"/>
                    <measurement group_id="O4" value="3.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Hematocrit (Ht) From the Day of Surgery</title>
        <description>Control group- iv placebo normal saline plus regular electrocautery.
iv TXA plus regular electrocautery.
iv placebo plus Aquamantys system and regular electrocautery.
iv TXA and Aquamantys system and regular electrocautery</description>
        <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
          </group>
          <group group_id="O2">
            <title>Aquamantys System</title>
            <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O3">
            <title>TXA Plus Aquamantys</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Hematocrit (Ht) From the Day of Surgery</title>
          <description>Control group- iv placebo normal saline plus regular electrocautery.
iv TXA plus regular electrocautery.
iv placebo plus Aquamantys system and regular electrocautery.
iv TXA and Aquamantys system and regular electrocautery</description>
          <units>Volume % of RBC in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.51"/>
                    <measurement group_id="O2" value="8.6" spread="3.22"/>
                    <measurement group_id="O3" value="6.8" spread="2.58"/>
                    <measurement group_id="O4" value="10.0" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Blood Loss</title>
        <description>The estimated blood loss was determined with the Gross formula [23]. According to a review article published in 2013, Gross’s formula though developed in 1983 is still widely used as reported. The formula which is relatively easy to use is described below:
Patient blood volume (PBV) = K (1) x height (m) 3 + K (2) x weight (kg) + K (3) Where K (1) = 0.3669 (male), 0.3561(female); K (2) = 0.03219 (male), 0.03308 (female); And K (3) = 0.6041(male), 0.1833 (female) Estimated blood loss = PBV [Hematocritinitial – Hematocritfinal ] / Hematocritmean Where mean hematocrit is the sum of initial and final hematocrit divided by two.</description>
        <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
          </group>
          <group group_id="O2">
            <title>Aquamantys System</title>
            <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O3">
            <title>TXA Plus Aquamantys</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Blood Loss</title>
          <description>The estimated blood loss was determined with the Gross formula [23]. According to a review article published in 2013, Gross’s formula though developed in 1983 is still widely used as reported. The formula which is relatively easy to use is described below:
Patient blood volume (PBV) = K (1) x height (m) 3 + K (2) x weight (kg) + K (3) Where K (1) = 0.3669 (male), 0.3561(female); K (2) = 0.03219 (male), 0.03308 (female); And K (3) = 0.6041(male), 0.1833 (female) Estimated blood loss = PBV [Hematocritinitial – Hematocritfinal ] / Hematocritmean Where mean hematocrit is the sum of initial and final hematocrit divided by two.</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747.9" spread="298"/>
                    <measurement group_id="O2" value="938.9" spread="376"/>
                    <measurement group_id="O3" value="746.6" spread="270"/>
                    <measurement group_id="O4" value="1077.6" spread="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost Analysis</title>
        <description>Charges per case.</description>
        <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
          </group>
          <group group_id="O2">
            <title>Aquamantys System</title>
            <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O3">
            <title>TXA Plus Aquamantys</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control: Standard Electro-cautery and Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Cost Analysis</title>
          <description>Charges per case.</description>
          <units>Dollars</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">IRB censored</measurement>
                    <measurement group_id="O2" value="NA">IRB censored</measurement>
                    <measurement group_id="O3" value="NA">IRB censored</measurement>
                    <measurement group_id="O4" value="NA">IRB censored</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Complications: deep venous thrombosis(DVT) or arterial thrombosis, pulmonary embolism(PE), myocardial infarction (MI), cerebrovascular accident (CVA)</description>
        <time_frame>day of surgery preoperative time to postoperative day 3 or postoperative day 2 if day 3 data are not recorded for the 4 groups</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
          </group>
          <group group_id="O2">
            <title>Aquamantys System</title>
            <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O3">
            <title>TXA Plus Aquamantys</title>
            <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Complications: deep venous thrombosis(DVT) or arterial thrombosis, pulmonary embolism(PE), myocardial infarction (MI), cerebrovascular accident (CVA)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid</title>
          <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
Tranexamic Acid: see arm/group descriptions</description>
        </group>
        <group group_id="E2">
          <title>Aquamantys System</title>
          <description>The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts
Aquamantys System: see arm/group descriptions</description>
        </group>
        <group group_id="E3">
          <title>TXA Plus Aquamantys</title>
          <description>TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.
The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20–200 watts.
Tranexamic Acid: see arm/group descriptions
Aquamantys System: see arm/group descriptions</description>
        </group>
        <group group_id="E4">
          <title>Control</title>
          <description>Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
Control Group: Saline and Standard Elecdrocautery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexandru Seviciu</name_or_title>
      <organization>Eastern Maine Medical Center</organization>
      <phone>207-973-5918</phone>
      <email>aseviciu@emhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

